Clinical Practice Guidelines
Oncotype DX® is included in both the American Society of
Clinical Oncology (ASCO) 2007 Update of Recommendations for the Use of Tumor
Markers in Breast Cancer and the National Comprehensive Cancer Network (NCCN)
Clinical Practice Guidelines in Oncology Breast Cancer to identify certain
subgroups of patients with node-negative, estrogen receptor-positive breast
cancer who may be successfully treated with hormonal therapy alone and may not
need chemotherapy.
ASCO: The Oncotype DX assay is recommended by the Updated ASCO
Clinical Guidelines for Use of Tumor Markers in Breast Cancer to identify:
-
Node-negative, ER-positive breast cancer patients with low recurrence risk who
may not benefit from adjuvant chemotherapy (specifically CMF/MF)1
-
Node-negative, ER-positive breast cancer patients with high recurrence risk who
may derive significant benefit from adjuvant chemotherapy (specifically CMF/MF)1
NCCN: The National Comprehensive Cancer Network (NCCN) annually updates
their comprehensive clinical practice guidelines for treatment recommendations
relying on evidence based consensus. The NCCN expert panel recommended in their
2008 Clinical Practice Guidelines consideration of the use of the Oncotype
DX test for estrogen receptor positive patients with the following clinical
features:
-
Tumor size 0.6-1.0cm, moderate/poorly differentiated or unfavorable features*;
or
-
Tumor size >1cm
*Unfavorable features: angiolymphatic invasion, high nuclear grade,
or high histologic grade.
For additional information on guidelines, please click on the following links:
|
 |
|
